1.
Actas Dermosifiliogr
; 115(6): T618-T624, 2024 Jun.
Artigo
em Inglês, Espanhol
| MEDLINE
| ID: mdl-38648932
2.
3.
Actas Dermosifiliogr
; 115(6): 618-624, 2024 Jun.
Artigo
em Inglês, Espanhol
| MEDLINE
| ID: mdl-38311227
4.
Actas Dermosifiliogr
; 114(1): 49-53, 2023 Jan.
Artigo
em Inglês, Espanhol
| MEDLINE
| ID: mdl-35963337
RESUMO
Immunosuppressants and immunomodulators are widely used in dermatology. Some of these drugs, however, can increase the risk of severe COVID-19. New antivirals against SARS-CoV-2 have been shown to reduce progression to COVID-19 pneumonia in susceptible patients, but their availability is limited. On May 23, 2022, the Spanish Agency for Medicines and Medical Devices (AEMPS) updated its priority eligibility criteria for SARS-CoV-2 antiviral therapy. In this practical guide, we review the indications for these new drugs and provide guidance on which patients with mild to moderate COVID might benefit from their use in dermatology.